Market Access/ News/ News/ Top stories J&J faces FTC probe on Remicade biosimilar defence Phil Taylor biosimilar, Inflectra, Johnson & Johnson, Pfizer, Remicade 0 Comment Johnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that Share X J&J faces FTC probe on Remicade biosimilar defence https://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/
biosimilar, Inflectra, Johnson & Johnson, Pfizer, Remicade
0 Comment
